Oncology Central

Personalized prediction scheme for myeloproliferative neoplasms developed

Researchers from the University of Cambridge, the Wellcome Sanger Institute and the Wellcome-MRC Cambridge Stem Cell Institute (all based in Cambridge, UK) have developed a personalized prediction scheme for myeloproliferative neoplasms, using new genetic and clinical information to better classify the disease.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.